Drug intelligence / Profile preview

BXT-255

Development stage: Preclinical
Lead developer: BioXyTran
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

BXT-255 is a preclinical-stage therapeutic candidate being developed by BioXyTran for the treatment of Traumatic Brain Injury (TBI). It is a member of the company's Hemo-Oxygenation platform, which utilizes hemoglobin-based oxygen carriers (HBOCs) to deliver oxygen to hypoxic tissues. BXT-255 is a chemically stabilized, copolymerized bovine hemoglobin molecule designed to address the secondary brain injury caused by tissue hypoxia following trauma. Due to its significantly smaller size compared to red blood cells, BXT-255 is intended to navigate constricted or partially blocked capillaries, thereby delivering oxygen directly to oxygen-deprived brain tissue and potentially improving clinical outcomes in TBI patients.

Beyond the preview

Go deeper on BXT-255.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BXT-255.

Explore the full profile